AstraZeneca merger talks with Bristol Myers Squibb spark market turmoil
Multiple reports suggested that British drugmaker AstraZeneca was negotiating a mega‑merger with U.S. rival Bristol Myers Squibb valued at roughly £300 billion ($400 billion). The speculation triggered a sharp sell‑off in AstraZeneca shares, which fell about 9 % and erased nearly £18 billion of market value, while raising concerns that the company might relocate its main stock‑market listing and headquarters to New York.
Analysts questioned the strategic rationale and highlighted the likelihood of extensive regulatory scrutiny on both sides of the Atlantic. Sources said the UK government had offered tentative backing provided the enlarged group would keep its headquarters in Britain, and investment bank Morgan Stanley was among the advisers.
Later, a confidential source told Reuters that no substantive negotiations had taken place. Following the denial, AstraZeneca shares rebounded 2.9 % and Bristol Myers Squibb fell 2.6 %, ending the brief rally of merger‑driven market anxiety.
Entities: AstraZeneca · AstraZeneca plc · BP · Bristol Myers Squibb · Morgan Stanley · Pascal Soriot · Shell · Unilever · United Kingdom Government
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Analysts expressed skepticism about the strategic rationale and noted likely regulatory hurdles in the UK and US.
- [○ 1 SOURCE] The UK government reportedly gave tentative backing to the deal on condition the enlarged company keep its headquarters in Britain.
- [○ 1 SOURCE] The proposed merger would have been one of the largest pharmaceutical deals globally.
- [○ 1 SOURCE] Following the denial of merger talks, AstraZeneca shares rose about 2.9 % while Bristol Myers Squibb shares fell about 2.6 %.
- [○ 1 SOURCE] Morgan Stanley was among the advisers on the proposed AstraZeneca‑Bristol Myers Squibb tie‑up.
- [● 3 SOURCES] AstraZeneca shares fell about 9 % and lost roughly £18 billion in market value after the merger speculation.
- [● 4 SOURCES] Reports suggested AstraZeneca and Bristol Myers Squibb were discussing a merger valued at about £300 billion.
- [○ 1 SOURCE] A confidential source said no substantive negotiations were taking place between AstraZeneca and Bristol Myers Squibb.